← Back to Company DatabaseVisit Website
Freenome
AI-powered blood tests for early cancer detection.
Series C+South San Francisco, CAFounded 2014
About
Freenome is developing a multiomics platform that combines cell-free DNA, methylation, and protein biomarkers with AI to detect cancer early. The company focuses on a blood-based test for colorectal cancer screening and plans to expand across multiple cancer types. Its approach integrates biology and machine learning for comprehensive blood test analysis.
Total Funding
$1.1BKey Product
Multiomics blood test for colorectal cancer screeningGeography
North AmericaKey Investors
a16zGoogle VenturesRoche
Focus Areas
Early Detection / ScreeningDiagnosticsAI / Machine Learning
Technology
Liquid BiopsyGenomics / SequencingAI / Machine Learning
Cancer Types
ColorectalPan-cancer
Last updated: Feb 4, 2026